Rapid P2Y12 Receptor Inhibition Attenuates Inflammatory Cell Infiltration in Thrombus Aspirated From the STEMI Patients
Status:
Completed
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
This is a prospective, randomized, parallel design study to investigate that ticagrelor could
attenuate inflammatory cell infiltration in thrombus aspirated from ST elevation myocardial
infarction (STEMI) patients. The anticipated duration of the study is approximately 9 months,
including an anticipated enrolment period of 8 months and follow-up period of 1 month.
Patients within 12 hours of symptom onset were randomly assigned in a one-to-one ratio to
receive ticagrelor or clopidogrel at time of STEMI diagnosis. The primary endpoint was the
extent of inflammatory cell infiltration in thrombus aspirated from STEMI patients, expressed
as number of total inflammatory cells per mm2 thrombus area.
Phase:
Phase 4
Details
Lead Sponsor:
First Affiliated Hospital of Harbin Medical University